Compounded Hair-Loss Topicals

White cream on a glass ointment slab with a spatula, unlabeled jars and an amber dropper bottle

Topical preparations combining agents used in androgenetic hair loss.

FDA-approved landscape first

Topical minoxidil is FDA approved for androgenetic alopecia. Oral finasteride is FDA approved for male androgenetic alopecia. Where an approved product meets the clinical need, it is generally the appropriate first consideration. Status: FDA-Approved Product.

Reproductive-risk precaution

Finasteride and dutasteride are contraindicated in women who are pregnant or may become pregnant. Exposure during pregnancy carries a risk of abnormal development of the external genitalia in a male fetus. Women who are or may become pregnant should not handle these preparations.

Actives and role

Minoxidil: the active in FDA-approved topical products.
Finasteride and dutasteride: 5-alpha-reductase inhibitors. No topical finasteride or dutasteride product is FDA approved, and dutasteride is not FDA approved for hair loss in the United States. Status: Off-Label Clinical Use.
Other actives a prescriber may include: azelaic acid, tretinoin, ketoconazole, diphenhydramine and spironolactone. None is FDA approved for hair loss.

Status: Compounded Option, with off-label components labeled.

Dosage forms

Solution, spray, cream.

Safety

Tretinoin is contraindicated in pregnancy. Topical preparations can be absorbed systemically. Use is directed by the prescriber.

Patients: Transfer a Prescription

Compounded preparations are not FDA approved. FDA does not review them for safety, effectiveness or quality before they are dispensed, and they are not equivalent to commercially available approved products. California requires a patient-specific prescription for a compounded preparation, and a pharmacy may not compound what is essentially a copy of a commercially available product unless the pharmacist documents a clinically significant difference for the individual patient or the product is in shortage. This page is general information, not medical advice.

References

Clinical review: Dor Keyvani, PharmD, Pharmacist-in-Charge, California pharmacist license RPH 75634. Clinically reviewed Oct. 20, 2026. Updated Nov. 10, 2026. See our Editorial Policy and Quality and Safety pages.